6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

See	VB	see	see	see	N	O
the	DT	the	the	the	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	VB	ribavirin	ribavirin	ribavirin	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
description	NN	description	description	descript	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
their	PRP$	their	their	their	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
35%	CD	35%	35%	35%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
and	CC	and	and	and	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
were	VBD	were	were	were	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Merck	NNP	merck	merck	merck	N	O
Sharp	NNP	sharp	sharp	sharp	N	O
Dohme	NNP	dohme	dohme	dohm	N	O
Corp	NNP	corp	corp	corp	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
subsidiary	NN	subsidiary	subsidiary	subsidiari	N	O
of	IN	of	of	of	N	O
Merck	NNP	merck	merck	merck	N	O
Co	NNP	co	co	co	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
4231	CD	4231	4231	4231	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
and	CC	and	and	and	N	O
otherwise	RB	otherwise	otherwise	otherwis	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
ADRs	NNP	adrs	adrs	adr	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
another	DT	another	another	anoth	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pancytopenia	NNP	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
35%	CD	35%	35%	35%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
investigator	NN	investigator	investigator	investig	N	O
's	POS	's	's	's	N	O
causality	NN	causality	causality	causal	N	O
assessment	NN	assessment	assessment	assess	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
when	WRB	when	when	when	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
and	CC	and	and	and	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
three	CD	three	three	three	N	O
times	NNS	times	time	time	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
was	VBD	was	wa	wa	N	O
assessed	VBN	assessed	assessed	assess	N	O
in	IN	in	in	in	N	O
2095	CD	2095	2095	2095	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
two	CD	two	two	two	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
previously	RB	previously	previously	previous	N	O
untreated	VBN	untreated	untreated	untreat	N	O
)	)	)	)	)	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
a	DT	a	a	a	N	O
four	CD	four	four	four	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
lead	JJ	lead	lead	lead	Y	O
-	:	-	-	-	N	O
in	IN	in	in	in	N	O
period	NN	period	period	period	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
previously	RB	previously	previously	previous	N	O
untreated	VBN	untreated	untreated	untreat	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
RESPOND	NNP	respond	respond	respond	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
failed	VBN	failed	failed	fail	N	O
previous	JJ	previous	previous	previou	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
800	CD	800	800	800	N	O
mg	NN	mg	mg	mg	N	O
three	CD	three	three	three	N	O
times	NNS	times	time	time	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
four	CD	four	four	four	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
lead	JJ	lead	lead	lead	Y	O
-	:	-	-	-	N	O
in	IN	in	in	in	N	O
period	NN	period	period	period	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
[	VBD	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
studied	VBD	studied	studied	studi	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
49	CD	49	49	49	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
39%	CD	39%	39%	39%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
82%	CD	82%	82%	82%	N	O
were	VBD	were	were	were	N	O
white	JJ	white	white	white	N	O
and	CC	and	and	and	N	O
15%	CD	15%	15%	15%	N	O
were	VBD	were	were	were	N	O
black	JJ	black	black	black	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
four	CD	four	four	four	N	O
week	NN	week	week	week	N	O
lead	SYM	lead	lead	lead	Y	O
-	:	-	-	-	N	O
in	IN	in	in	in	N	O
period	NN	period	period	period	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
,	,	,	,	,	N	O
28	CD	28	28	28	N	O
1263	CD	1263	1263	1263	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
experienced	VBD	experienced	experienced	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
entire	JJ	entire	entire	entir	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
13%	CD	13%	13%	13%	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
and	CC	and	and	and	N	O
12%	CD	12%	12%	12%	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Events	NNS	events	event	event	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
previous	JJ	previous	previous	previou	N	O
studies	NNS	studies	study	studi	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
.	.	.	.	.	N	O

Only	RB	only	only	onli	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	VB	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
drug	NN	drug	drug	drug	N	O
(	(	(	(	(	N	O
primarily	RB	primarily	primarily	primarili	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
and	CC	and	and	and	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
39%	CD	39%	39%	39%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
24%	CD	24%	24%	24%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reason	NN	reason	reason	reason	N	O
for	IN	for	for	for	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
was	VBD	was	wa	wa	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
investigator	NN	investigator	investigator	investig	N	O
's	POS	's	's	's	N	O
causality	NN	causality	causality	causal	N	O
assessment	NN	assessment	assessment	assess	N	O
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
and	CC	and	and	and	N	O
reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
than	IN	than	than	than	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
in	IN	in	in	in	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
RESPOND	NNP	respond	respond	respond	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
Reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
Combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
and	CC	and	and	and	N	O
Reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Rate	NNP	rate	rate	rate	N	O
of	IN	of	of	of	N	O
5%	CD	5%	5%	5%	N	O
than	IN	than	than	than	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
Previously	RB	previously	previously	previous	N	O
Untreated	VBN	untreated	untreated	untreat	N	O
(	(	(	(	(	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
Previous	NNP	previous	previous	previou	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Failures	NNP	failures	failure	failur	N	O
(	(	(	(	(	N	O
RESPOND	NNP	respond	respond	respond	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Reporting	VBG	reporting	reporting	report	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
Percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Reporting	VBG	reporting	reporting	report	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1225	CD	1225	1225	1225	N	O
)	)	)	)	)	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
467	CD	467	467	467	N	O
)	)	)	)	)	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
323	CD	323	323	323	N	O
)	)	)	)	)	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
80	CD	80	80	80	N	O
)	)	)	)	)	N	O

Median	JJ	median	median	median	N	O

Exposure	NN	exposure	exposure	exposur	N	O
(	(	(	(	(	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
197	CD	197	197	197	N	O
216	CD	216	216	216	N	O
253	CD	253	253	253	N	O
104	CD	104	104	104	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
50	CD	50	50	50	N	O
30	CD	30	30	30	N	O
45	CD	45	45	45	N	O
20	CD	20	20	20	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
19	CD	19	19	19	N	O
14	CD	14	14	14	N	O
10	CD	10	10	10	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
46	CD	46	46	46	N	O
42	CD	42	42	42	N	O
43	CD	43	43	43	N	O
38	CD	38	38	38	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
35	CD	35	35	35	N	O
16	CD	16	16	16	N	O
44	CD	44	44	44	N	O
11	CD	11	11	11	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
25	CD	25	25	25	N	O
22	CD	22	22	22	N	O
24	CD	24	24	24	N	O
16	CD	16	16	16	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
20	CD	20	20	20	N	O
13	CD	13	13	13	N	O
15	CD	15	15	15	N	O
8	CD	8	8	8	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
Mouth	NNP	mouth	mouth	mouth	N	I-AdverseReaction
11	CD	11	11	11	N	O
10	CD	10	10	10	N	O
15	CD	15	15	15	N	O
9	CD	9	9	9	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
58	CD	58	58	58	N	O
59	CD	59	59	59	N	O
55	CD	55	55	55	N	O
50	CD	50	50	50	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
34	CD	34	34	34	N	O
29	CD	29	29	29	N	O
33	CD	33	33	33	N	O
30	CD	30	30	30	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
18	CD	18	18	18	N	O
21	CD	21	21	21	N	O
16	CD	16	16	16	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Appetite	NNP	appetite	appetite	appetit	N	I-AdverseReaction
25	CD	25	25	25	N	O
24	CD	24	24	24	N	O
26	CD	26	26	26	N	O
16	CD	16	16	16	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
19	CD	19	19	19	N	O
23	CD	23	23	23	N	O
16	CD	16	16	16	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
19	CD	19	19	19	N	O
16	CD	16	16	16	N	O
16	CD	16	16	16	N	O
10	CD	10	10	10	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
34	CD	34	34	34	N	O
34	CD	34	34	34	N	O
30	CD	30	30	30	N	O
24	CD	24	24	24	N	O

Irritability	NNP	irritability	irritability	irrit	Y	B-AdverseReaction
22	CD	22	22	22	N	O
23	CD	23	23	23	N	O
21	CD	21	21	21	N	O
13	CD	13	13	13	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
Exertional	NNP	exertional	exertional	exert	N	I-AdverseReaction
8	CD	8	8	8	N	O
8	CD	8	8	8	N	O
11	CD	11	11	11	N	O
5	CD	5	5	5	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
27	CD	27	27	27	N	O
27	CD	27	27	27	N	O
22	CD	22	22	22	N	O
16	CD	16	16	16	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
Skin	NNP	skin	skin	skin	N	I-AdverseReaction
18	CD	18	18	18	N	O
18	CD	18	18	18	N	O
22	CD	22	22	22	N	O
9	CD	9	9	9	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
17	CD	17	17	17	N	O
19	CD	19	19	19	N	O
16	CD	16	16	16	N	O
6	CD	6	6	6	N	O

Other	JJ	other	other	other	N	O
Important	NNP	important	important	import	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

Among	IN	among	among	among	N	O

subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
previously	RB	previously	previously	previous	N	O
untreated	VBN	untreated	untreated	untreat	N	O
subjects	NNS	subjects	subject	subject	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
failed	VBD	failed	failed	fail	N	O
previous	JJ	previous	previous	previou	N	O
therapy	NN	therapy	therapy	therapi	N	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
notable	JJ	notable	notable	notabl	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
seriousness	NN	seriousness	seriousness	serious	N	O
,	,	,	,	,	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
increased	JJ	increased	increased	increas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
only	RB	only	only	onli	N	O
peginterferon	JJ	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
(	(	(	(	(	N	O
alteration	NN	alteration	alteration	alter	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
taste	NN	taste	taste	tast	N	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
reported	VBD	reported	reported	report	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	VB	ribavirin	ribavirin	ribavirin	N	O
alone	RB	alone	alone	alon	N	O
(	(	(	(	(	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NNS	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Values	NNS	values	value	valu	N	O

Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
selected	JJ	selected	selected	select	N	O
hematological	JJ	hematological	hematological	hematolog	N	O
parameters	NNS	parameters	parameter	paramet	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
and	CC	and	and	and	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O

Decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
dosage	NN	dosage	dosage	dosag	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
ribavirin	VBN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
peginterferon	VB	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
must	MD	must	must	must	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	O
and	CC	and	and	and	N	O
Platelets	NNS	platelets	platelet	platelet	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
neutrophil	NNS	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
and	CC	and	and	and	N	O
platelet	NN	platelet	platelet	platelet	N	I-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
had	VBD	had	had	had	N	O
platelet	VBN	platelet	platelet	platelet	N	B-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
50	CD	50	50	50	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	O
or	CC	or	or	or	N	O
platelets	NNS	platelets	platelet	platelet	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
dosage	NN	dosage	dosage	dosag	N	O
or	CC	or	or	or	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
peginterferon	VBN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
is	VBZ	is	is	is	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
must	MD	must	must	must	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
Selected	NNP	selected	selected	select	N	O
Hematological	NNP	hematological	hematological	hematolog	N	O
Parameters	NNS	parameters	parameter	paramet	N	O

Previously	RB	previously	previously	previous	N	O
Untreated	VBN	untreated	untreated	untreat	N	O
(	(	(	(	(	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
SPRINT	NNP	sprint	sprint	sprint	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
Previous	NNP	previous	previous	previou	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Failures	NNP	failures	failure	failur	N	O
(	(	(	(	(	N	O
RESPOND	NNP	respond	respond	respond	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Percentage	NN	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
Reporting	VBG	reporting	reporting	report	N	O
Selected	NNP	selected	selected	select	N	O
Hematological	NNP	hematological	hematological	hematolog	N	O
Parameters	NNP	parameters	parameter	paramet	N	O
Percentage	NNP	percentage	percentage	percentag	N	O
of	IN	of	of	of	N	O
Subjects	NNP	subjects	subject	subject	N	O
Reporting	NNP	reporting	reporting	report	N	O
Selected	NNP	selected	selected	select	N	O
Hematological	NNP	hematological	hematological	hematolog	N	O
Parameters	NNS	parameters	parameter	paramet	N	O

Hematological	JJ	hematological	hematological	hematolog	N	O
Parameters	NNS	parameters	parameter	paramet	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1225	CD	1225	1225	1225	N	O
)	)	)	)	)	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
467	CD	467	467	467	N	O
)	)	)	)	)	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
323	CD	323	323	323	N	O
)	)	)	)	)	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
80	CD	80	80	80	N	O
)	)	)	)	)	N	O

Hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction

(	(	(	(	(	N	I-AdverseReaction
g	VB	g	g	g	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
)	)	)	)	)	N	I-AdverseReaction

10	CD	10	10	10	N	I-AdverseReaction
49	CD	49	49	49	N	O
29	CD	29	29	29	N	O
49	CD	49	49	49	N	O
25	CD	25	25	25	N	O

8.5	CD	8.5	8.5	8.5	N	I-AdverseReaction
6	CD	6	6	6	N	O
3	CD	3	3	3	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Neutrophils	NNP	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
(	(	(	(	(	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
)	)	)	)	)	N	I-AdverseReaction

0.75	CD	0.75	0.75	0.75	N	I-AdverseReaction
31	CD	31	31	31	N	O
18	CD	18	18	18	N	O
26	CD	26	26	26	N	O
13	CD	13	13	13	N	O

0.5	CD	0.5	0.5	0.5	N	I-AdverseReaction
8	CD	8	8	8	N	O
4	CD	4	4	4	N	O
7	CD	7	7	7	N	O
4	CD	4	4	4	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
(	(	(	(	(	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
)	)	)	)	)	N	I-AdverseReaction

50	CD	50	50	50	N	I-AdverseReaction
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

25	CD	25	25	25	N	I-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
mouth	NN	mouth	mouth	mouth	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
;	:	;	;	;	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
eosinophilia	NNS	eosinophilia	eosinophilia	eosinophilia	Y	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
systemic	JJ	systemic	systemic	system	N	I-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
DRESS	NNP	dress	dress	dress	N	B-AdverseReaction
)	)	)	)	)	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
exfoliative	JJ	exfoliative	exfoliative	exfoli	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
exfoliative	JJ	exfoliative	exfoliative	exfoli	N	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
,	,	,	,	,	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
eruption	NN	eruption	eruption	erupt	Y	I-AdverseReaction
,	,	,	,	,	N	O
toxicoderma	VBD	toxicoderma	toxicoderma	toxicoderma	Y	B-AdverseReaction
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
:	:	:	:	:	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
(	(	(	(	(	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
birth	NN	birth	birth	birth	N	B-AdverseReaction
defects	NNS	defects	defect	defect	N	I-AdverseReaction
and	CC	and	and	and	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
;	:	;	;	;	N	O
avoid	JJ	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
female	JJ	female	female	femal	N	O
partners	NNS	partners	partner	partner	N	O
of	IN	of	of	of	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
must	MD	must	must	must	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
negative	JJ	negative	negative	neg	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
test	NN	test	test	test	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
therapy	NN	therapy	therapy	therapi	N	O
;	:	;	;	;	N	O
use	VB	use	use	use	N	O
two	CD	two	two	two	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
contraception	NN	contraception	contraception	contracept	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
monthly	JJ	monthly	monthly	monthli	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
tests	NNS	tests	test	test	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
-	:	-	-	-	N	O
The	DT	the	the	the	N	O
addition	NN	addition	addition	addit	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
to	TO	to	to	to	N	O
peginterferon	VB	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	JJ	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	VB	ribavirin	ribavirin	ribavirin	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
-	:	-	-	-	N	O
The	DT	the	the	the	N	O
addition	NN	addition	addition	addit	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
to	TO	to	to	to	N	O
peginterferon	VB	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
worsening	NN	worsening	worsening	worsen	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	JJ	ribavirin	ribavirin	ribavirin	N	O
therapy	NN	therapy	therapy	therapi	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
-	:	-	-	-	N	O
Serious	JJ	serious	serious	seriou	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
,	,	,	,	,	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Embryofetal	NN	embryofetal	embryofetal	embryofet	N	O

Toxicity	NNP	toxicity	toxicity	toxic	N	O
(	(	(	(	(	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
)	)	)	)	)	N	O

Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
birth	NN	birth	birth	birth	N	B-AdverseReaction
defects	NNS	defects	defect	defect	N	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
exposed	JJ	exposed	exposed	expos	N	I-AdverseReaction
fetus	NN	fetus	fetus	fetu	N	I-AdverseReaction
.	.	.	.	.	N	O

Extreme	NNP	extreme	extreme	extrem	N	O
care	NN	care	care	care	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
partners	NNS	partners	partner	partner	N	O
of	IN	of	of	of	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
started	VBN	started	started	start	N	O
unless	IN	unless	unless	unless	N	O
a	DT	a	a	a	N	O
report	NN	report	report	report	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
negative	JJ	negative	negative	neg	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
test	NN	test	test	test	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
obtained	VBN	obtained	obtained	obtain	N	O
immediately	RB	immediately	immediately	immedi	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
for	IN	for	for	for	N	O
additional	JJ	additional	additional	addit	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	JJ	potential	potential	potenti	N	O
and	CC	and	and	and	N	O
men	NNS	men	men	men	N	O
must	MD	must	must	must	N	O
use	VB	use	use	use	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
two	CD	two	two	two	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
has	VBZ	has	ha	ha	N	O
concluded	VBN	concluded	concluded	conclud	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
contraception	NN	contraception	contraception	contracept	Y	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
combined	JJ	combined	combined	combin	N	O
oral	JJ	oral	oral	oral	N	O
contraceptive	JJ	contraceptive	contraceptive	contracept	N	O
product	NN	product	product	product	N	O
containing	VBG	containing	containing	contain	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
norethindrone	NN	norethindrone	norethindrone	norethindron	N	O
.	.	.	.	.	N	O

Oral	JJ	oral	oral	oral	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
containing	VBG	containing	containing	contain	N	O
lower	JJR	lower	lower	lower	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
norethindrone	NN	norethindrone	norethindrone	norethindron	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
contraception	NN	contraception	contraception	contracept	Y	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
or	CC	or	or	or	N	O
are	VBP	are	are	are	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
.	.	.	.	.	N	O

Routine	NNP	routine	routine	routin	N	O
monthly	JJ	monthly	monthly	monthli	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
tests	NNS	tests	test	test	N	O
must	MD	must	must	must	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
during	IN	during	during	dure	N	O
this	DT	this	this	thi	N	O
time	NN	time	time	time	N	O
[	VBZ	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Anemia	NNP	anemia	anemia	anemia	Y	O
(	(	(	(	(	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
)	)	)	)	)	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
addition	NN	addition	addition	addit	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
to	TO	to	to	to	N	O
peginterferon	VB	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	B-AdverseReaction
decrease	NN	decrease	decrease	decreas	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	JJ	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
(	(	(	(	(	N	O
with	IN	with	with	with	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
differential	JJ	differential	differential	differenti	N	O
counts	NNS	counts	count	count	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
obtained	VBN	obtained	obtained	obtain	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Weeks	NNP	weeks	week	week	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
at	IN	at	at	at	N	O
other	JJ	other	other	other	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hemoglobin	VBN	hemoglobin	hemoglobin	hemoglobin	Y	O
is	VBZ	is	is	is	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10	CD	10	10	10	N	O
g	JJ	g	g	g	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
hemoglobin	VBN	hemoglobin	hemoglobin	hemoglobin	Y	O
is	VBZ	is	is	is	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
8.5	CD	8.5	8.5	8.5	N	O
g	JJ	g	g	g	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
,	,	,	,	,	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
ribavirin	VBN	ribavirin	ribavirin	ribavirin	N	O
is	VBZ	is	is	is	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
for	IN	for	for	for	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
peginterferon	VB	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
must	MD	must	must	must	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
for	IN	for	for	for	N	O
additional	JJ	additional	additional	addit	N	O
information	NN	information	information	inform	N	O
regarding	VBG	regarding	regarding	regard	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
less	RBR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
g	JJ	g	g	g	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
8.5	CD	8.5	8.5	8.5	N	I-AdverseReaction
g	JJ	g	g	g	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

With	IN	with	with	with	N	O
the	DT	the	the	the	N	O
interventions	NNS	interventions	intervention	intervent	N	O
used	VBN	used	used	use	N	O
for	IN	for	for	for	N	O
anemia	JJ	anemia	anemia	anemia	Y	O
management	NN	management	management	manag	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
average	JJ	average	average	averag	N	O
additional	JJ	additional	additional	addit	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
1	CD	1	1	1	N	O
g	NNS	g	g	g	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
g	JJ	g	g	g	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
dL	NN	dl	dl	dl	N	I-AdverseReaction
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
among	IN	among	among	among	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
and	CC	and	and	and	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
71	CD	71	71	71	N	O
days	NNS	days	day	day	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
15	CD	15	15	15	N	O
-	:	-	-	-	N	O
337	CD	337	337	337	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
71	CD	71	71	71	N	O
days	NNS	days	day	day	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
range	NN	range	range	rang	N	O
of	IN	of	of	of	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
337	CD	337	337	337	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Certain	NNP	certain	certain	certain	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
exertional	JJ	exertional	exertional	exert	N	B-AdverseReaction
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	I-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
(	(	(	(	(	N	O
generally	RB	generally	generally	gener	N	O
of	IN	of	of	of	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
)	)	)	)	)	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
anemia	VB	anemia	anemia	anemia	Y	B-AdverseReaction
occurred	JJ	occurred	occurred	occur	N	O
twice	RB	twice	twice	twice	N	O
as	RB	as	a	as	N	O
often	RB	often	often	often	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
anemia	VB	anemia	anemia	anemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
erythropoiesis	NN	erythropoiesis	erythropoiesis	erythropoiesi	N	O
stimulating	VBG	stimulating	stimulating	stimul	N	O
agents	NNS	agents	agent	agent	N	O
(	(	(	(	(	N	O
ESAs	NNP	esas	esas	esa	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
permitted	VBN	permitted	permitted	permit	N	O
for	IN	for	for	for	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
investigator	NN	investigator	investigator	investig	N	O
's	POS	's	's	's	N	O
discretion	NN	discretion	discretion	discret	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
ribavirin	NNS	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
an	DT	an	an	an	N	O
ESA	NNP	esa	esa	esa	N	O
was	VBD	was	wa	wa	N	O
43%	CD	43%	43%	43%	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
24%	CD	24%	24%	24%	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	O
was	VBD	was	wa	wa	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

Thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ESA	NNP	esa	esa	esa	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
disease	NN	disease	disease	diseas	N	O
states	NNS	states	state	state	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
among	IN	among	among	among	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
among	IN	among	among	among	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
ESA	NNP	esa	esa	esa	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
definite	JJ	definite	definite	definit	N	O
causality	NN	causality	causality	causal	N	O
assessment	NN	assessment	assessment	assess	N	O
or	CC	or	or	or	N	O
benefit	NN	benefit	benefit	benefit	N	O
risk	NN	risk	risk	risk	N	O
assessment	NN	assessment	assessment	assess	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
confounding	VBG	confounding	confounding	confound	N	O
factors	NNS	factors	factor	factor	N	O
and	CC	and	and	and	N	O
lack	NN	lack	lack	lack	N	O
of	IN	of	of	of	N	O
randomization	NN	randomization	randomization	random	N	O
of	IN	of	of	of	N	O
ESA	NNP	esa	esa	esa	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
randomized	VBN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
parallel	JJ	parallel	parallel	parallel	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
previously	RB	previously	previously	previous	N	O
untreated	JJ	untreated	untreated	untreat	N	O
CHC	NNP	chc	chc	chc	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
genotype	JJ	genotype	genotype	genotyp	N	O
1	CD	1	1	1	N	O
infection	NN	infection	infection	infect	Y	O
to	TO	to	to	to	N	O
compare	VB	compare	compare	compar	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
ESA	NNP	esa	esa	esa	N	O
versus	NN	versus	versus	versu	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
for	IN	for	for	for	N	O
initial	JJ	initial	initial	initi	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
b	NN	b	b	b	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

Similar	JJ	similar	similar	similar	N	O
SVR	NNP	svr	svr	svr	N	O
rates	NNS	rates	rate	rate	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
an	DT	an	an	an	N	O
ESA	NNP	esa	esa	esa	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ESAs	NNP	esas	esas	esa	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
events	NNS	events	event	event	N	O
including	VBG	including	including	includ	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
embolism	NN	embolism	embolism	embol	Y	O
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
accident	NN	accident	accident	accid	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
deep	JJ	deep	deep	deep	N	O
vein	NN	vein	vein	vein	N	O
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
ribavirin	VB	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
alone	RB	alone	alone	alon	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
rate	NN	rate	rate	rate	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
anemia	VB	anemia	anemia	anemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
ESA	NNP	esa	esa	esa	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
transfusion	NN	transfusion	transfusion	transfus	Y	O
rate	NN	rate	rate	rate	N	O
was	VBD	was	wa	wa	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
ESA	NNP	esa	esa	esa	N	O
.	.	.	.	.	N	O

Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
anemia	NN	anemia	anemia	anemia	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
(	(	(	(	(	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
seven	CD	seven	seven	seven	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
had	VBD	had	had	had	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	B-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
0.5	CD	0.5	0.5	0.5	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
alone	RB	alone	alone	alon	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
subjects	NNS	subjects	subject	subject	N	O
experienced	VBD	experienced	experienced	experienc	N	O
severe	JJ	severe	severe	sever	N	B-Severity
or	CC	or	or	or	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	JJ	threatening	threatening	threaten	N	I-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
two	CD	two	two	two	N	O
subjects	NNS	subjects	subject	subject	N	O
experienced	VBD	experienced	experienced	experienc	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	VBG	threatening	threatening	threaten	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
combination	NN	combination	combination	combin	N	O
of	IN	of	of	of	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
with	IN	with	with	with	N	O
PegIntron	NNP	pegintron	pegintron	pegintron	N	O
REBETOL	NNP	rebetol	rebetol	rebetol	N	O
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
(	(	(	(	(	N	O
with	IN	with	with	with	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
differential	JJ	differential	differential	differenti	N	O
counts	NNS	counts	count	count	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
obtained	VBN	obtained	obtained	obtain	N	O
at	IN	at	at	at	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Weeks	NNP	weeks	week	week	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
at	IN	at	at	at	N	O
other	JJ	other	other	other	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

Decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	O
counts	NNS	counts	count	count	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
peginterferon	VBN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
are	VBP	are	are	are	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
must	MD	must	must	must	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
for	IN	for	for	for	N	O
additional	JJ	additional	additional	addit	N	O
information	NN	information	information	inform	N	O
regarding	VBG	regarding	regarding	regard	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Pancytopenia	NNP	pancytopenia	pancytopenia	pancytopenia	Y	O
(	(	(	(	(	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Alfa	NNP	alfa	alfa	alfa	N	O
)	)	)	)	)	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
(	(	(	(	(	N	O
with	IN	with	with	with	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
differential	JJ	differential	differential	differenti	N	O
counts	NNS	counts	count	count	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
obtained	VBN	obtained	obtained	obtain	N	O
at	IN	at	at	at	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Weeks	NNP	weeks	week	week	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
at	IN	at	at	at	N	O
other	JJ	other	other	other	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
and	CC	and	and	and	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
for	IN	for	for	for	N	O
guidelines	NNS	guidelines	guideline	guidelin	N	O
for	IN	for	for	for	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
parameters	NNS	parameters	parameter	paramet	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Serious	JJ	serious	serious	seriou	N	B-Severity
acute	JJ	acute	acute	acut	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
,	,	,	,	,	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
such	PDT	such	such	such	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
immediately	RB	immediately	immediately	immedi	N	O
instituted	VBD	instituted	instituted	institut	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O

See	VB	see	see	see	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
for	IN	for	for	for	N	O
a	DT	a	a	a	N	O
listing	NN	listing	listing	list	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
VICTRELIS	NNP	victrelis	victrelis	victr	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
potentially	RB	potentially	potentially	potenti	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
significant	JJ	significant	significant	signific	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
virologic	JJ	virologic	virologic	virolog	N	O
activity	NN	activity	activity	activ	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Please	NNP	please	please	pleas	N	O
refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
Table	VB	table	table	tabl	N	O
5	CD	5	5	5	N	O
for	IN	for	for	for	N	O
established	VBN	established	established	establish	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
potentially	RB	potentially	potentially	potenti	N	O
significant	JJ	significant	significant	signific	N	O
drug	NN	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.3	CD	7.3	7.3	7.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NN	rna	rna	rna	N	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
at	IN	at	at	at	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Weeks	NNP	weeks	week	week	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
12	CD	12	12	12	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
24	CD	24	24	24	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
follow	SYM	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	RB	up	up	up	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
real	JJ	real	real	real	N	O
-	:	-	-	-	N	O
time	NN	time	time	time	N	O
reverse	JJ	reverse	reverse	revers	N	O
-	:	-	-	-	N	O
transcription	NN	transcription	transcription	transcript	N	O
polymerase	NN	polymerase	polymerase	polymeras	N	O
chain	NN	chain	chain	chain	N	O
reaction	NN	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
RT	NNP	rt	rt	rt	N	O
-	:	-	-	-	N	O
PCR	NN	pcr	pcr	pcr	Y	O
)	)	)	)	)	N	O
assay	NN	assay	assay	assay	N	O
for	IN	for	for	for	N	O
monitoring	VBG	monitoring	monitoring	monitor	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NN	rna	rna	rna	N	O
levels	NNS	levels	level	level	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
assay	NN	assay	assay	assay	N	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NNP	rna	rna	rna	N	O
quantification	NN	quantification	quantification	quantif	N	O
of	IN	of	of	of	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
25	CD	25	25	25	N	O
IU	NNP	iu	iu	iu	N	O
per	IN	per	per	per	N	O
mL	NN	ml	ml	ml	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NNP	rna	rna	rna	N	O
detection	NN	detection	detection	detect	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
IU	NNP	iu	iu	iu	N	O
per	IN	per	per	per	N	O
mL	NN	ml	ml	ml	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
the	DT	the	the	the	N	O
purposes	NNS	purposes	purpose	purpos	N	O
of	IN	of	of	of	N	O
assessing	VBG	assessing	assessing	assess	N	O
Response	NNP	response	response	respons	N	O
-	:	-	-	-	N	O
Guided	VBD	guided	guided	guid	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
milestones	NNS	milestones	milestone	mileston	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
confirmed	JJ	confirmed	confirmed	confirm	N	O
"	NN	"	"	"	N	O
detectable	NN	detectable	detectable	detect	N	O
but	CC	but	but	but	N	O
below	IN	below	below	below	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
quantification	NN	quantification	quantification	quantif	N	O
"	NNP	"	"	"	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NNP	rna	rna	rna	N	O
result	NN	result	result	result	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
"	NN	"	"	"	N	O
undetectable	JJ	undetectable	undetectable	undetect	N	O
"	NN	"	"	"	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NNP	rna	rna	rna	N	O
result	NN	result	result	result	N	O
(	(	(	(	(	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
"	NNP	"	"	"	N	O
Target	NNP	target	target	target	N	O
Not	RB	not	not	not	N	O
Detected	NNP	detected	detected	detect	N	O
"	NNP	"	"	"	N	O
or	CC	or	or	or	N	O
"	NNP	"	"	"	N	O
HCV	NNP	hcv	hcv	hcv	N	O
-	:	-	-	-	N	O
RNA	NNP	rna	rna	rna	N	O
Not	RB	not	not	not	N	O
Detected	NNP	detected	detected	detect	N	O
"	NNP	"	"	"	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
with	IN	with	with	with	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
differential	JJ	differential	differential	differenti	N	O
counts	NNS	counts	count	count	N	O
)	)	)	)	)	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
obtained	VBN	obtained	obtained	obtain	N	O
at	IN	at	at	at	N	O
pretreatment	NN	pretreatment	pretreatment	pretreat	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Weeks	NNP	weeks	week	week	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
12	CD	12	12	12	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
closely	RB	closely	closely	close	N	O
at	IN	at	at	at	N	O
other	JJ	other	other	other	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

Refer	NN	refer	refer	refer	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
peginterferon	NN	peginterferon	peginterferon	peginterferon	N	O
alfa	NN	alfa	alfa	alfa	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
for	IN	for	for	for	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
testing	VBG	testing	testing	test	N	O
recommendations	NNS	recommendations	recommendation	recommend	N	O
including	VBG	including	including	includ	N	O
hematology	NN	hematology	hematology	hematolog	N	O
,	,	,	,	,	N	O
biochemistry	NN	biochemistry	biochemistry	biochemistri	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
testing	NN	testing	testing	test	N	O
requirements	NNS	requirements	requirement	requir	N	O
.	.	.	.	.	N	O

